Navigation Links
Abnormal chromosome indicator of treatment and outcome in patients with rare brain tumor
Date:1/19/2012

A recent analysis of clinical trial results performed by the Radiation Therapy Oncology Group (RTOG) demonstrate that a chromosomal abnormalityspecifically, the absence (co-deletion) of chromosomes 1p and 19qhave definitive prognostic and predictive value for managing the treatment of adult patients with pure and mixed anaplastic oligodendrogliomas. The presence of the chromosomal abnormality was associated with a substantially better prognosis and near-doubling of median survival time when treatment with combined chemotherapy and radiation therapy was compared to treatment with radiation therapy alone.

Oligodendrogliomas are uncommon tumors that represent approximately 4.0% of all brain tumors. Mixed oliogdendrogliomas (those also containing astrocytic elements) account for 1.0% of all brain tumors. Pure and mixed oligodendrogliomas that contain anaplastic (malignant) cells typically grow more rapidly than non-anaplastic tumors.

The RTOG 9402 trial A Phase III Intergroup Randomized Comparison of Radiation Alone vs. Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic Oligodendrogliomas was conducted with four other National Cancer Institute (NCI)-supported cooperative groups. Trial participants had a pathologically confirmed pure or mixed anaplastic oligodendroglioma and were randomly assigned into one of two treatment arms. The 148 participants randomized to Arm 1 were treated with PCV (procarbazine, CCNU [lomustine] and vincristine) chemotherapy and radiation therapy (RT), and the 143 participants randomized to Arm 2 were treated with RT alone.

RTOG 9402 study results reported with a minimum follow-up time of 3 years in the Journal of Clinical Oncology (2006 Jun 20; 24(18): 2707-14) showed no survival benefit for patients treated with early PVC chemotherapy plus RT over RT alone. Although a significant impact on median progression-free survival time was realized (2.6 years versus 1.7 years for RT alone), the regimen was associated with significantly more adverse side effects. The study authors also reported that study participants in both arms whose tumor lacked chromosomes 1p and 19q had longer median survival times as compared with participants without these deletions (> 7 vs. 2.8 years, respectively). This led the study authors to conclude that "tumors with 1p and 19q co-deletion are less aggressive or more responsive to PCV chemotherapy or both."

A recent analysis undertaken of the RTOG 9402 data (at a median study participant follow-up time of 11 years) is planned for submission to the 2012 American Society of Clinical Oncology Annual Meeting. However, due to the finding's significance for patient care, results are reported here in advance of submission.

The abstract reports that the 126 study participants with 1p and 19q co-deletion, the median survival time (MST) of 59 participants randomized to the PCV chemotherapy and RT arm was much longer than the 67 participants randomized to the RT alone arm (14.7 years vs. 7.3 years). Interestingly, for study participants whose tumors contained only one deletion (either 1p or 19q) or no deletions, no difference was found in MST between the two treatment arms (2.6 years vs. 2.7 years).

"The profound association between improved outcome for patients who lack the 1p and 19q chromosomes and were treated with PCV chemotherapy and radiation therapy has significant implication for patients with anaplastic oligodendrogliomas. We now have unequivocal evidence that the chromosomal structure of 1p and 19q co-deletion can be used as a marker to determine which patients will benefit from combined chemotherapy and radiation therapy" says the principal investigator for the RTOG 9402 trial and the abstract's primary author J. Gregory Cairncross, MD, Professor and Head of the Department of Clinical Neurosciences at the University of Calgary, Alberta, Canada.

The other NCI-supported cooperative groups participating in the intergroup (INT 0149) trial are the Eastern Oncology Cooperative Group, SWOG, North Central Cancer Treatment Group, and the NCIC Clinical Trials Group.

"These are exciting and practice-changing results," says Walter J. Curran, Jr., MD, RTOG Group Chair and Executive Director of the Winship Cancer Institute of Emory University in Atlanta. "Given the low incidence of this disease, this achievement required the close collaboration of many groups and centers and everyone associated with the trial should be proud of the accomplishment."


'/>"/>
Contact: Shawn Farley
PR@acr.org
703-648-8936
American College of Radiology
Source:Eurekalert

Related medicine news :

1. Statins may increase risk of interstitial lung abnormalities in smokers
2. Depression and anxiety not linked to delayed resolution of abnormal mammograms, Pap tests
3. Antidepressant linked to developmental brain abnormalities in rodents
4. Could Airway Abnormality Point to Autism?
5. Abnormal Protein May Explain Loss of Smell With Alzheimers
6. Scientists identify a key molecule that blocks abnormal blood vessel growth in tumors
7. Brain Blood Flow Abnormalities Persist in Gulf War Vets
8. Mutant gene identified that causes abnormal chromosome count, leading to cancer
9. Abnormal liver tests associated with increased death rates in people over 75
10. Abnormal brain ultrasounds in premature infants indicate future risk of psychiatric disorders
11. Hereditary colon cancer syndrome marked by abnormally dense blood vessel growth in mouth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... March 22, 2017 , ... Soriant recognizes that identifying savings ... Healthcare facilities across the country are always forced to focus on costs ... across the country, an efficient and quick way to estimate savings potential within ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... cure Rett Syndrome, a devastating neurological disorder that afflicts 350,000 individuals worldwide. ... the X chromosome, and almost exclusively strikes females. Following a normal infancy, ...
(Date:3/22/2017)... ... ... Last year, 43 million gallons of surplus milk was reportedly dumped by U.S. ... can be caused by several factors, one pharmaceutical company CEO suggests high rates of ... a sugar found in milk and milk products. It is estimated that ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... and related services to communities across eastern Texas, is announcing a charity drive ... meals to hungry children and adults. , Consistently a top-rated nonprofit organization ...
(Date:3/22/2017)... ... March 22, 2017 , ... Martin J. Mitchell Insurance, a ... communities throughout central Ohio, is initiating a charity drive to raise support for ... Defense and the Veteran's Brain Injury Center conclude that more than one in ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... , March 22, 2017 ... Manufacturing Organization (CDMO), held a special event to introduce ... in Lexington, Kentucky . The inaugural ... Piramal Group Chairman Ajay Piramal, and Piramal Pharma ... ...
(Date:3/22/2017)... FinancialBuzz.com News Commentary  ... According to a report by the New ... billion in 2016, and is projected to grow at a compound ... billion by 2025. The medical cannabis market is projected to grow ... 2016, to an estimated $13.3 billion in 2025. These projections do ...
(Date:3/22/2017)... ROCKLAND, Mass. , March 22, 2017 EMD ... Germany , in the U.S. and Canada ... be presented during the poster presentation session at the 65 ... Indian Wells, California on March 24 ... on analyses of a real-world database collected from July 2009 ...
Breaking Medicine Technology: